GFP expression by intracellular gene delivery of GFP-coding fragments using nanocrystal quantum dots

Nanotechnology

Volumn 19, Issue 49, 2008, Pages

  Hoshino, Akiyoshi ^a,b   Manabe, Noriyoshi ^a,c   Fujioka, Kouki ^a   Hanada, Sanshiro ^a,c   Yasuhara, Masato ^b   Kondo, Akihiko ^d   Yamamoto, Kenji ^a,b  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c Japan Association for the Advancement of Medical Equipment   (Japan)

^d KOBE UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINES; ANIMAL CELL CULTURE; CELL CULTURE; CUSTOMER SATISFACTION; FLUORESCENCE; GENE TRANSFER; GENETIC ENGINEERING; LIPOSOMES; MAMMALS; OPTICAL WAVEGUIDES; PHOSPHOLIPIDS; PROGRAMMING THEORY; PROTEINS; QUANTUM ELECTRONICS; VECTORS;

CULTURE MEDIAS; ELECTRONIC CHARGES; ENHANCED GREEN FLUORESCENT PROTEINS; EXPRESSION EFFICIENCIES; GENE DELIVERIES; GENE FUNCTIONS; GENE THERAPIES; GFP EXPRESSIONS; INTRACELLULAR DELIVERIES; INTRACELLULAR GENE DELIVERIES; MAMMALIAN CELLS; MULTIPLE FACTORS; NANOCRYSTAL QUANTUM DOTS; NUCLEAR LOCALIZING SIGNALS; ONCOGENESIS; PROMOTER ELEMENTS; QUANTUM DOTS; VIRAL VECTORS;

SEMICONDUCTOR QUANTUM DOTS;

DNA FRAGMENT; ENHANCED GREEN FLUORESCENT PROTEIN; GREEN FLUORESCENT PROTEIN; NANOCRYSTAL; PEPTIDE; QUANTUM DOT;

ARTICLE; CONTROLLED STUDY; CULTURE MEDIUM; FLUORESCENCE; GENE CONSTRUCT; GENE EXPRESSION; GENE INDUCTION; GENE STRUCTURE; GENE TARGETING; MAMMAL CELL; NUCLEAR LOCALIZATION SIGNAL; PARTICLE SIZE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION;

EID: 58149214073     PISSN: 09574484     EISSN: 13616528     Source Type: Journal    
DOI: 10.1088/0957-4484/19/49/495102     Document Type: Article

References (54)

1. Flotte T R, Brantly M L, Spencer L T, Byrne B J, Spencer C T, Baker D J and Humphries M 2004 Phase I trial of intramuscular injection of a recombinant adeno-associated virus alpha 1-antitrypsin (rAAV2-CB-hAAT) gene vector to AAT-deficient adults Hum. Gene Ther. 15 93-128
2. Brantly M L et al 2006 Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alphal-antitrypsin (AAT) vector in AAT-deficient adults Hum. Gene Ther. 17 1177-86
3. Flotte T R et al 2003 Phase I trial of intranasal and endobronchial administration of a recombinant adeno-associated virus serotype 2 (rAAV2)-CFTR vector in adult cystic fibrosis patients: a two-part clinical study Hum. Gene Ther. 14 1079-88
4. Wagner J A et al 2002 A phase II, double-blind, randomized, placebo-controlled clinical trial of tgAAVCF using maxillary sinus delivery in patients with cystic fibrosis with antrostomies Hum. Gene Ther. 13 1349-59
5. Kay M A et al 2000 Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector Nat. Genet. 24 257-61
6. Manno C S et al 2003 AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B Blood 101 2963-72
7. Eberling J L, Jagust W J, Christine C W, Starr P, Larson P, Bankiewicz K S and Aminoff M J 2008 Results from a phase I safety trial of hAADC gene therapy for Parkinson disease Neurology 70 1980-3
8. Johnson P R et al 2005 Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques J. Virol. 79 955-65
9. Manno C S et al 2006 Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response Nat. Med. 12 342-7
10. Lin J, Zhi Y, Mays L and Wilson J M 2007 Vaccines based on novel adeno-associated virus vectors elicit aberrant CD8+ T-cell responses in mice J. Virol. 81 11840-9
11. Lin J, Calcedo R, Vandenberghe L H, Figueredo J M and Wilson J M 2008 Impact of preexisting vector immunity on the efficacy of adeno-associated virus-based HIV-1 Gag vaccines Hum. Gene Ther. 19 663-9
12. Themis M et al 2005 Oncogenesis following delivery of a nonprimate lentiviral gene therapy vector to fetal and neonatal mice Mol. Ther. 12 763-71
13. Van Ginkel F W, Liu C, Simecka J W, Dong J Y, Greenway T, Frizzell R A, Kiyono H, McGhee J R and Pascual D W 1995 Intratracheal gene delivery with adenoviral vector induces elevated systemic IgG and mucosal IgA antibodies to adenovirus and beta-galactosidase Hum. Gene Ther. 6 895-903
14. McCoy R D, Davidson B L, Roessler B J, Huffnagle G B, Janich S L, Laing T J and Simon R H 1995 Pulmonary inflammation induced by incomplete or inactivated adenoviral particles Hum. Gene Ther. 6 1553-60
15. Schaffert D and Wagner E 2008 Gene therapy progress and prospects: synthetic polymer-based systems Gene Ther.
16. Zou Y, Zong G, Ling Y H and Perez-Soler R 2000 Development of cationic liposome formulations for intratracheal gene therapy of early lung cancer Cancer Gene. Ther. 7 683-96
17. Dzau V J, Mann M J, Morishita R and Kaneda Y 1996 Fusigenic viral liposome for gene therapy in cardiovascular diseases Proc. Natl Acad. Sci. USA 93 11421-5
18. McKay T, Patel M, Pickles R J, Johnson L G and Olsen J C 2006 Influenza M2 envelope protein augments avian influenza hemagglutinin pseudotyping of lentiviral vectors Gene Ther. 13 715-24
19. Kaneda Y, Nakajima T, Nishikawa T, Yamamoto S, Ikegami H, Suzuki N, Nakamura H, Morishita R and Kotani H 2002 Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system Mol. Ther. 6 219-26
20. Honma K, Takeshita F and Ochiya T 2007 Application of atelocollagen-mediated siRNA delivery for RNAi therapies Yakugaku Zasshi 127 807-12
21. Dufes C, Uchegbu I F and Schatzlein A G 2005 Dendrimers in gene delivery Adv. Drug Deliv. Rev. 57 2177-202
22. Eliyahu H, Barenholz Y and Domb A J 2005 Polymers for DNA delivery Molecules 10 34-64
23. Itaka K, Ohba S, Miyata K, Kawaguchi H, Nakamura K, Takato T, Chung U I and Kataoka K 2007 Bone regeneration by regulated in vivo gene transfer using biocompatible polyplex nanomicelles Mol. Ther. 15 1655-62
24. Akagi D, Oba M, Koyama H, Nishiyama N, Fukushima S, Miyata T, Nagawa H and Kataoka K 2007 Biocompatible micellar nanovectors achieve efficient gene transfer to vascular lesions without cytotoxicity and thrombus formation Gene Ther. 14 1029-38
25. Hsieh J M, Ho M L, Wu P W, Chou P T, Tsai T T and Chi Y 2006 Iridium-complex modified CdSe/ZnS quantum dots; a conceptual design for bi-functionality toward imaging and photosensitization Chem. Commun. 615-7
26. Voura E B, Jaiswal J K, Mattoussi H and Simon S M 2004 Tracking metastatic tumor cell extravasation with quantum dot nanocrystals and fluorescence emission-scanning microscopy Nat. Med. 10 993-8
27. Dubertret B, Skourides P, Norris D J, Noireaux V, Brivanlou A H and Libchaber A 2002 In vivo imaging of quantum dots encapsulated in phospholipid micelles Science 298 1759-62
28. Takeda M, Tada H, Higuchi H, Kobayashi Y, Kobayashi M, Sakurai Y, Ishida T and Ohuchi N 2008 In vivo single molecular imaging and sentinel node navigation by nanotechnology for molecular targeting drug-delivery systems and tailor-made medicine Breast Cancer 15 145-52
29. Akerman M E, Chan W C, Laakkonen P, Bhatia S N and Ruoslahti E 2002 Nanocrystal targeting in vivo Proc. Natl Acad. Sci. USA 99 12617-21
30. Kim S et al 2004 Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping Nat. Biotechnol. 22 93-7
31. Hoshino A, Kawamura Y I, Yasuhara M, Toyama-Sorimachi N, Yamamoto K, Matsukawa A, Lira S A and Dohi T 2007 Inhibition of CCL1-CCR8 interaction prevents aggregation of macrophages and development of peritoneal adhesions J. Immunol. 178 5296-304
32. Hoshino A et al 2007 Trafficking of QD-conjugated MPO-ANCA in murine systemic vasculitis and glomerulonephritis model mice Microbiol. Immunol. 51 551-66
33. Ebbesen M and Jensen T G 2006 Nanomedicine: techniques, potentials, and ethical implications J. Biomed. Biotechnol. 2006 51516
34. Freitas R A Jr 2005 Nanotechnology, nanomedicine and nanosurgery Int. J. Surg. 3 243-6
35. Caruthers S D, Wickline S A and Lanza G M 2007 Nanotechnological applications in medicine Curr. Opin. Biotechnol. 18 26-30
36. Navalakhe R M and Nandedkar T D 2007 Application of nanotechnology in biomedicine Indian J. Exp. Biol. 45 160-5
37. Arayne M S and Sultana N 2006 Review: nanoparticles in drug delivery for the treatment of cancer Pak. J. Pharm. Sci. 19 258-68
38. Lin H and Datar R H 2006 Medical applications of nanotechnology Natl Med. J. India 19 27-32
39. Hoshino A, Ito-Ihara T, Ishida-Okawara A, Muso E, Yamamoto K and Suzuki K 2006 Detection of neutrophil MPO in patient with rapidly progressive glumerulonephritis J. Med. Technol. 50 1409-15
40. Hoshino A, Fujioka K, Oku T, Nakamura S, Suga M, Yamaguchi Y, Suzuki K, Yasuhara M and Yamamoto K 2004 Quantum dots targeted to the assigned organelle in living cells Microbiol. Immunol. 48 985-94
41. Bhakta G, Mitra S and Maitra A 2005 DNA encapsulated magnesium and manganous phosphate nanoparticles: potential non-viral vectors for gene delivery Biomaterials 26 2157-63
42. Bharali D J, Klejbor I, Stachowiak E K, Dutta P, Roy I, Kaur N, Bergey E J, Prasad P N and Stachowiak M K 2005 Organically modified silica nanoparticles: a nonviral vector for in vivo gene delivery and expression in the brain Proc. Natl Acad. Sci. USA 102 11539-44
43. Jia N, Lian Q, Shen H, Wang C, Li X and Yang Z 2007 Intracellular delivery of quantum dots tagged antisense oligodeoxynucleotides by functionalized multiwalled carbon nanotubes Nano Lett. 7 2976-80
44. Biju V, Muraleedharan D, Nakayama K, Shinohara Y, Itoh T, Baba Y and Ishikawa M 2007 Quantum dot-insect neuropeptide conjugates for fluorescence imaging, transfection, and nucleus targeting of living cells Langmuir 23 10254-61
45. Srinivasan C, Lee J, Papadimitrakopoulos F, Silbart L K, Zhao M and Burgess D J 2006 Labeling and intracellular tracking of functionally active plasmid DNA with semiconductor quantum dots Mol. Ther. 14 192-201
46. Matsushita M, Tomizawa K, Moriwaki A, Li S T, Terada H and Matsui H 2001 A high-efficiency protein transduction system demonstrating the role of PKA in long-lasting long-term potentiation J. Neurosci. 21 6000-7
47. Hoshino A, Hanaki K, Suzuki K and Yamamoto K 2004 Applications of T-lymphoma labeled with fluorescent quantum dots to cell tracing markers in mouse body Biochem. Biophys. Res. Commun. 314 46-53
48. Hoshino A, Fujioka K, Oku T, Suga M, Sasaki Y F, Ohta T, Yasuhara M, Suzuki K and Yamamoto K 2004 Physicochemical properties and cellular toxicity of nanocrystal quantum dots depend on their surface modification Nano Lett. 4 2163-9
49. Hoshino A, Manabe N, Fujioka K, Suzuki K, Yasuhara M and Yamamoto K 2007 Use of fluorescent quantum dot bioconjugates for cellular imaging of immune cells, cell organelle labeling, and nanomedicine: surface modification regulates biological function, including cytotoxicity J. Artif. Organs 10 149-57
50. Fujioka K et al 2008 Luminescent passive-oxidized silicon quantum dots as biological staining labels and their cytotoxicity effects at high concentration Nanotechnology 19 415102
51. Shiohara A, Hoshino A, Hanaki K, Suzuki K and Yamamoto K 2004 On the cyto-toxicity caused by quantum dots Microbiol. Immunol. 48 669-75
52. Hoshino A, Omata K, Takami S, Adschiri T, Terada N, Funatsu T, Yasuhara M and Yamamoto K 2007 Fluorescence millisecond oscillation in polar solvents regulates fluorescence intensity of colloidal quantum dots' solution J. Nanophoton. 1 013516
53. Hanaki K, Momo A, Oku T, Komoto A, Maenosono S, Yamaguchi Y and Yamamoto K 2003 Semiconductor quantum dot/albumin complex is a long-life and highly photostable endosome marker Biochem. Biophys. Res. Commun. 302 496-501
54. Hardman R 2006 A toxicologic review of quantum dots: toxicity depends on physicochemical and environmental factors Environ. Health Perspect. 114 165-72